8.93

1.36% 0.12

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$8.81

Offen:

$8.85

24-Stunden-Volumen:

2.05M

Relative Volume:

0.91

Marktkapitalisierung:

$1.55B

Einnahmen:

$25.55M

Nettoeinkommen (Verlust:

$-341.97M

KGV:

-3.1893

EPS:

-2.8

Netto-Cashflow:

$-304.44M

1W Leistung:

+0.11%

1M Leistung:

+12.47%

6M Leistung:

+161.11%

1J Leistung:

+125.51%

1-Tages-Spanne:

$8.85

$9.54

1-Wochen-Bereich:

$8.35

$9.54

52-Wochen-Spanne:

$1.775

$9.54

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

617-370-8837

Adresse

60 HAMPSHIRE STREET, CAMBRIDGE

Mitarbeiter

197

Twitter

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	8.93	1.53B	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-26	Hochstufung	Oppenheimer	Perform → Outperform
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-04-17	Eingeleitet	Wells Fargo	Equal Weight
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

Feb 13, 2026

Will Relay Therapeutics Inc. benefit from government policy2025 Price Targets & Free Community Supported Trade Ideas - mfd.ru

Feb 13, 2026

Can Relay Therapeutics Inc. expand its profit marginsPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru

Feb 13, 2026

Feb 11, 2026

Can Relay Therapeutics Inc. sustain its profitability2025 Bull vs Bear & Low Risk High Reward Trade Ideas - mfd.ru

Feb 11, 2026

Feb 10, 2026

Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com South Africa

Feb 10, 2026

Feb 09, 2026

Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat

Feb 09, 2026

Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com

Feb 09, 2026

Feb 08, 2026

Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm

Feb 08, 2026

Feb 07, 2026

Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance

Feb 07, 2026

Feb 06, 2026

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail

Feb 06, 2026

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga

Feb 05, 2026

Feb 04, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network

Feb 04, 2026

Feb 03, 2026

Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter

Feb 03, 2026

Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com

Feb 03, 2026

Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView

Feb 03, 2026

Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire

Feb 03, 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - The Manila Times

Feb 03, 2026

Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Feb 03, 2026

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz

Feb 02, 2026

Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance

Feb 02, 2026

Feb 01, 2026

Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn

Feb 01, 2026

Jan 31, 2026

Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026